Neovascular glaucoma treatment in 2012: Role of anti-VEGF agents

被引：3
|
作者：
Kodjikian, L. [1 ]
机构：
[1] Univ Lyon 1, Serv Ophtalmol, Hop Croix Rousse, F-69004 Lyon, France
来源：
JOURNAL FRANCAIS D OPHTALMOLOGIE | 2013年 / 36卷 / 05期
关键词：
Neovascular glaucoma; Avastin (R); Bevacizumab; Anti-VEGF; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; ANGLE NEOVASCULARIZATION; IRIS NEOVASCULARIZATION; RUBEOSIS IRIDIS; AQUEOUS-HUMOR; INJECTION; TRABECULECTOMY; AVASTIN(R); OUTCOMES;
D O I：
10.1016/j.jfo.2012.10.012
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Neovascular glaucoma is a serious pathology with a variety of causes. It results from the secretion by hypoxic retinal tissue of growth factors, including vascular endothelial growth factor ( VEGF). Anterior segment involvement begins in the iris, followed by the development of a fibrovascular membrane in the angle, with resultant goniosynechiae. Treatment of the underlying disease consists most often of panretinal photocoagulation. As for the secondary sequelae, current treatment consists of intravitreal injection of anti-VEGF agents. The most utilized agent is bevacizumab or Avastin (R), off-label. Avastin (R) is effective against neovascularization and ocular hypertension, especially in the early stages. It also represents an adjunct to filtering surgery. It appears to be very well tolerated. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：461 / 465
页数：5
相关论文
共 50 条
  • [1] Role of Anti-VEGF (Bevacizumab) in Management of Neovascular Glaucoma: A Review
    Alharfy, Abdulrahman Arshed N.
    Albalawi, Marwan Saleh D.
    Alzahrani, Abdulmajeed Mousa
    Alsubaie, Ruby Naif M.
    Albalawi, Amani Ahmad S.
    Alkaabneh, Waad Ali
    Altidlawi, Abdullah Ibrahim
    Alharbi, Amal Nafea J.
    Almutairi, Afnan Mohammed H.
    Alotabi, Rola Ali S.
    [J]. JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2021, 33 (40A) : 215 - 221
  • [2] The Optimization of an Anti-VEGF Therapeutic Regimen for Neovascular Glaucoma
    Bai, Ling
    Wang, Yanfen
    Liu, Xindi
    Zheng, Yuping
    Wang, Wenjing
    He, Na
    Tariq, Farheen
    Wang, Feng
    Zhang, Shu
    [J]. FRONTIERS IN MEDICINE, 2022, 8
  • [3] Anti-VEGF Treatment of Glaucoma
    Bendel, Rick E.
    [J]. CURRENT DRUG THERAPY, 2012, 7 (02) : 126 - 130
  • [4] Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term
    Yaoyao Sun
    Yong Liang
    Peng Zhou
    Huijuan Wu
    Xianru Hou
    Zeqin Ren
    Xiaoxin Li
    Mingwei Zhao
    [J]. BMC Ophthalmology, 16
  • [5] Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term
    Sun, Yaoyao
    Liang, Yong
    Zhou, Peng
    Wu, Huijuan
    Hou, Xianru
    Ren, Zeqin
    Li, Xiaoxin
    Zhao, Mingwei
    [J]. BMC OPHTHALMOLOGY, 2016, 16
  • [6] Use of Anti-VEGF Agents in Glaucoma Surgery
    Slabaugh, Mark
    Salim, Sarwat
    [J]. JOURNAL OF OPHTHALMOLOGY, 2017, 2017
  • [7] Anti-VEGF Intravitreal Bevacizumab for Radiation-Associated Neovascular Glaucoma
    Nagendran, Sonali T.
    Finger, Paul T.
    [J]. Ophthalmic Surgery Lasers & Imaging Retina, 2015, 46 (02): : 201 - 207
  • [8] Evaluation of Anti-VEGF Treatment in Peripapillary Neovascular Membranes
    Arceneaux, Richard
    Venzara, Frank
    Thomley, Martin L.
    Feist, Richard M.
    Albert, Michael A.
    Mason, John O.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [9] Anti-VEGF agents in the treatment of RVO
    Rehak, Matus
    [J]. ACTA OPHTHALMOLOGICA, 2013, 91
  • [10] Treatment of neovascular glaucoma by Anti VEGF injections and laser
    Maschi, C.
    [J]. ACTA OPHTHALMOLOGICA, 2014, 92
12345